Who are Low-dose epinephrine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epinephrine (Adrenaline), Normal saline with epinephrine, Normal saline and epinephrine, Epinephrin 0.07, Racemic adrenaline, epinephrine perfusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-epinephrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Low-dose epinephrine — Competitive Intelligence Brief

Low-dose epinephrine (Low-dose epinephrine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine / Catecholamine. Area: Cardiovascular / Critical Care.

marketed Sympathomimetic amine / Catecholamine Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors Cardiovascular / Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Low-dose epinephrine (Low-dose epinephrine) — Icahn School of Medicine at Mount Sinai. Low-dose epinephrine acts as a sympathomimetic agent that stimulates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and cardiac output.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Low-dose epinephrine TARGET	Low-dose epinephrine	Icahn School of Medicine at Mount Sinai	marketed	Sympathomimetic amine / Catecholamine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Epinephrine (Adrenaline)	Epinephrine (Adrenaline)	Aga Khan University	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Normal saline with epinephrine	Normal saline with epinephrine	West Penn Allegheny Health System	marketed	Sympathomimetic amine / Vasopressor	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Normal saline and epinephrine	Normal saline and epinephrine	Le Bonheur Children's Hospital	marketed	Sympathomimetic amine and crystalloid fluid	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Epinephrin 0.07	Epinephrin 0.07	Kasr El Aini Hospital	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Racemic adrenaline	Racemic adrenaline	Oslo University Hospital	marketed	Sympathomimetic amine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
epinephrine perfusion	epinephrine perfusion	Central Hospital, Nancy, France	marketed	Sympathomimetic amine / Catecholamine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine / Catecholamine class)

Central Hospital, Nancy, France · 1 drug in this class
Children's Hospital of Eastern Ontario · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low-dose epinephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-epinephrine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab